Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Brokerages

Evolus, Inc. (NASDAQ:EOLS) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

EOLS has been the subject of a number of recent research reports. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently modified their holdings of EOLS. Rhumbline Advisers lifted its holdings in shares of Evolus by 2.0% during the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after purchasing an additional 1,657 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Evolus by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after acquiring an additional 1,838 shares during the period. Invesco Ltd. boosted its holdings in shares of Evolus by 7.5% during the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after acquiring an additional 2,383 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares during the period. Finally, Quantbot Technologies LP raised its holdings in shares of Evolus by 15.4% during the second quarter. Quantbot Technologies LP now owns 29,731 shares of the company’s stock valued at $274,000 after purchasing an additional 3,971 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Stock Down 1.5%

Shares of EOLS stock traded down $0.09 during mid-day trading on Thursday, reaching $5.94. 10,539 shares of the company’s stock traded hands, compared to its average volume of 1,021,845. The company’s 50-day moving average price is $6.48 and its 200-day moving average price is $5.49. The company has a market cap of $391.27 million, a P/E ratio of -8.87 and a beta of 1.32. Evolus has a 12 month low of $3.86 and a 12 month high of $9.35.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Equities analysts predict that Evolus will post -0.38 earnings per share for the current year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.